Yahoo MoviesDraftKings Poised to Shoot 30%-Plus Higher, Says Analyst
A Sanford C. Bernstein prognosticator believes the company can produce double-digit growth in its dedicated user base for many years.
A Sanford C. Bernstein prognosticator believes the company can produce double-digit growth in its dedicated user base for many years.
No pigeon, or indeed Pidgeon, was harmed in the incident at Stormont's finance committee.
You'll have no trouble from the neighbours!
The supermarket says it has begun consulting with workers over a major restructuring of its business.
during the forecast period. The market has a promising growth potential due to several factors, including growing market competitiveness leading to availability of cost-effective RFID solutions, high returns on investment, and increasing regulations and government initiatives for various industries.New York, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "RFID Market with COVID-19 Impact Analysis by Product Type, Wafer Size, Tag Type, Frequency, Applications, Form Factor, Material And Region - Global Forecast to 2026" - https://www.reportlinker.com/p04975552/?utm_source=GNW Moreover, increasing installation of RFID systems in manufacturing units to improve productivity due to COVID-19 could play a key role in driving the growth of the RFID market.Tags is projected to be the largest segment of the RFID market during the forecast periodThe tags is projected to be the largest segment of the RFID market, by products.Tags are the key components in an RFID solution and make up for the major part of the market due to bulk and multiple applications.Due to this, the segment captured the largest share of the market in 2020.The number of tags installed is much higher than the number of readers and software used in the RFID ecosystem of an organization.Additionally, with the rising number of assets, the installation of tags increases; however, existing readers can be used to scan new tags. This is the main reason due to which the market for tags is the largest.Passive tags segment is projected to register a larger market share by 2026The passive tags segment is projected to register a larger market share by 2026.The market for passive tags is expected to grow in applications such as retail, supply chain, transportation, aerospace, and sports.The factors contributing to the growth of passive tags in these applications are the low cost of tags and their increasing precision in data storage and reading distance.The penetration of RAIN RFID has further boosted the market of ultra-high-frequency passive tags, as this frequency is globally adaptable by manufacturers and customers.This is another key reason for the growth of the RFID market for passive tags.Ultra-high-frequency (UHF) tags segment of the RFID market is projected to register the highest CAGR during the forecast periodThe ultra-high-frequency (UHF) tags segment of the RFID market is projected to register the highest CAGR during the forecast period.UHF RFID tags offer the longest read range and highest reading speed among all frequencies.UHF passive tags can be read from an average distance of about 5–6 meters; larger UHF passive tags can be read from more than 30 meters in ideal conditions.Active tags have the longest read range of around 150 meters.These tags are more efficient than low- and high-frequency tags.Passive UHF tags are also less costly than low- and high-frequency tags.This is the key reason for customers preferring passive UHF tags.Logistics and supply chain application is projected to grow at the highest CAGR during the forecast periodThe logistics and supply chain application is projected to grow at the highest CAGR during the forecast period.The growth of this segment is contributed to the high adoption of tracking systems by logistics organizations to track and monitor their cargo in transit through air, road, or sea.Companies are also using sensor-based RFID tagging systems to monitor environmental conditions around the products being transported. Any deviation in the properties or external parameters is notified to the stakeholders, and appropriate action can be taken to prevent the damage.APAC is projected to become the fastest geographical market between 2021 and 2026The APAC is projected to grow at the highest CAGR during the forecast period.With the growing trade network among the countries in APAC, companies are leveraging RFID solutions to obtain visibility into supply chain operations.RFID is an ideal medium for tracking assets or people in organizations in real time. The adoption of RFID solutions across various industries, such as manufacturing, sports & entertainment, logistics and supply chain, and retail, is expected to increase in APAC during the forecast period.Breakdown of profiles of primary participants:• By Company: Tier 1 = 35%, Tier 2 = 45%, and Tier 3 = 20%• By Designation: C-level Executives = 40%, Directors = 35%, and Others (sales, marketing, and product managers, as well as members of various organizations) = 25%• By Region: APAC = 25%, Americas = 45%, and EMEA=30%Major players profiled in this report:The RFID market is dominated by a few globally established players such as Avery Dennison (US), Zebra Technologies (US), Honeywell (US), NXP Semiconductors (Netherlands), Impinj (US), HID Global (US), GAO RFID (Canada), Identiv (US), Invengo (China), and Nedap (Netherlands).Research coverageThis report offers detailed insights into the RFID market based on product type (tags, readers, and software and services), wafer size (8 inch and others), tag type (active tags and passive tags), frequency (low frequency, high frequency, and ultra-high frequency (UHF)), application (agriculture, commercial, transportation, healthcare, logistics & supply chain, aerospace, defense, retail, security and access control, sports, animal tracking, and ticketing), form factor (card, implant, key fob, label, paper ticket, band, and others), material (plastic, paper, glass, and others), and region (Americas, Europe, Middle East, and Africa (EMEA), and Asia Pacific (APAC)).The report also provides a comprehensive review of market drivers, restraints, opportunities, and challenges in the RFID market. The report also covers qualitative aspects in addition to the quantitative aspects of these markets.Key Benefits of Buying the ReportThe report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments.This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies.The report also helps stakeholders understand the pulse of the RFID market and provides them information on key market drivers, restraints, challenges, and opportunities.Read the full report: https://www.reportlinker.com/p04975552/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
Fires that appear to have been deliberately set destroyed more than 500 structures this week in and around Ethiopia's Gijet town, an analysis of satellite imagery shared with Reuters has found, adding credence to reports of continued conflict in parts of the northern region of Tigray. Prime Minister Abiy Ahmed declared victory over a rebellious regional force, the Tigray People's Liberation Front (TPLF), at the end of November after its fighters withdrew from the region's main cities and towns. The government has acknowledged isolated incidents of shooting but has said that most fighting has stopped in Tigray.
TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:G4S plc1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)Non-UK issuer 2. Reason for the notification (please mark the appropriate box or boxes with an “X”)An acquisition or disposal of voting rights An acquisition or disposal of financial instrumentsXAn event changing the breakdown of voting rights Other (please specify)iii: 3. Details of person subject to the notification obligationivNameThe Goldman Sachs Group, Inc.City and country of registered office (if applicable)Corporation Trust Center, 1209 Orange Street, Wilmington DE 19801, USA4. Full name of shareholder(s) (if different from 3.)vNameGoldman Sachs InternationalCity and country of registered office (if applicable)Plumtree Court, 25 Shoe Lane, London EC4A 4AU,UK5. Date on which the threshold was crossed or reachedvi:22/02/20216. Date on which issuer notified (DD/MM/YYYY):24/02/20217. Total positions of person(s) subject to the notification obligation % of voting rights attached to shares (total of 8. A)% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)Total of both in % (8.A + 8.B)Total number of voting rights held in issuerviiResulting situation on the date on which threshold was crossed or reached0.03%6.86%6.89%1,551,594,436Position of previous notification (if applicable)0.90%5.38%6.28% 8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviiiA: Voting rights attached to sharesClass/type of sharesISIN code (if possible)Number of voting rightsix% of voting rightsDirect(DTR5.1)Indirect (DTR5.2.1)Direct(DTR5.1)Indirect(DTR5.2.1)GB00B01FLG62 465,366 0.03%US37441W1080 21,105 0.001% SUBTOTAL 8. A486,4710.03% B 1: Financial Instruments according to DTR5.3.1R (1) (a)Type of financial instrumentExpiration datexExercise/ Conversion PeriodxiNumber of voting rights that may be acquired if the instrument is exercised/converted.% of voting rightsSecurities LendingOpen 85,584,4945.52% SUBTOTAL 8. B 185,584,4945.52% B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)Type of financial instrumentExpiration datexExercise/ Conversion Period xiPhysical or cash settlementxiiNumber of voting rights % of voting rightsRefer to the Annexure SUBTOTAL 8.B.220,798,1411.34% 9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)XNamexv% of voting rights if it equals or is higher than the notifiable threshold% of voting rights through financial instruments if it equals or is higher than the notifiable thresholdTotal of both if it equals or is higher than the notifiable thresholdThe Goldman Sachs Group, Inc. Goldman Sachs (UK) L.L.C. Goldman Sachs Group UK Limited Goldman SachsInternational 6.86%6.86% The Goldman Sachs Group, Inc. Goldman Sachs & Co. LLC The Goldman Sachs Group, Inc. GSAM Holdings LLC Goldman Sachs Asset Management, L.P. The Goldman Sachs Group, Inc. IMD Holdings LLC United Capital Financial Partners, Inc. United Capital Financial Advisers, LLC 10. In case of proxy voting, please identify:Name of the proxy holderN/AThe number and % of voting rights heldN/AThe date until which the voting rights will be heldN/A 11. Additional informationxviPlease note, the total amount of voting rights have been rounded to 2 decimal places therefore there is a possibility of a rounding error. Place of completionLondonDate of completion24/02/2021
Record Revenue of $614.1 Million and $167.3 Million for Full Year and Fourth Quarter 2020 Despite COVID-19 Impact Received Positive CHMP Opinion for VAZKEPA® in Europe and Continue to Advance Commercial Launch Plans for Europe Management to Host Conference Call Today at 7:30 a.m. ET DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the quarter and year ended December 31, 2020 and provided an update on company operations. Recent Key Amarin Achievements: Record revenue led by increased VASCEPA® (icosapent ethyl) use in the United States: Annual net total revenue of $614.1 million in 2020, an increase of 43% compared with 2019, consistent with guidance provided at the beginning of 2021. Fourth quarter of 2020 net total revenue was $167.3 million, an increase of 17% compared with the fourth quarter of 2019 and the highest quarterly net total revenue to date.Europe launch on-track for 2021: Received a positive opinion from the Committee on Human Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending market authorization in Europe for icosapent ethyl (brand name VAZKEPA® in Europe) for cardiovascular risk reduction.Mainland China and Hong Kong approval expected near the end of 2021: As submitted by our partner, Edding, in Mainland China the Chinese National Medical Products Administration (NMPA) has accepted for review icosapent ethyl. On a separate track, in Hong Kong, the Hong Kong Department of Health is evaluating icosapent ethyl. Medical guidelines of the Chinese Society of Cardiology (CSC) updated to recommend use of icosapent ethyl in China.Strong balance sheet: Ended 2020 with $563.4 million in total cash and investments and no debt. Management Commentary “We entered 2021 well positioned to further grow VASCEPA revenue in the U.S. while expanding internationally as we continue to lead the creating of an important new paradigm in preventative cardiovascular care beyond cholesterol management for at-risk patients,” stated John F. Thero, president and chief executive officer. “Our record revenue for the fourth quarter and full year of 2020, despite the headwinds we faced from the COVID-19 pandemic, underscores the large, untapped market need for VASCEPA in its new indication of persistent cardiovascular risk (P-CVR) reduction in the United States. We continue to focus our efforts on increasing awareness and education of P-CVR and VASCEPA’s demonstrated benefits in reducing that risk as proven in the landmark REDUCE-IT® study.” “The positive CHMP opinion, as recently announced, leads us to expect the European Commission to render its formal approval of VAZKEPA in April 2021. The CHMP opinion and anticipated approval are significant milestones for Amarin that brings us closer to making this important drug available in Europe to millions of patients at high risk of cardiovascular events such as heart attacks and strokes. Our growing commercial team in Europe is advancing commercial launch plans with unbranded engagement, and preliminary market access discussions are underway in certain key markets.” “Our global expansion plans are being further advanced by the progress of our partner in the China region, Edding, which includes Mainland China, Hong Kong, Macau and Taiwan. Edding is making tremendous progress across several key initiatives critical to the successful approval and launch of VASCEPA in the region, including the positive readout from their pivotal Phase 3 clinical study, inclusion of icosapent ethyl in the treatment guidelines of the CSC, the acceptance of the regulatory filing related to Mainland China with the NMPA and the introduction of VASCEPA in the Hainan Boao Lecheng International Medical Tourism Pilot Zone program. The China region represents a very significant market opportunity and we continue to work closely with Edding in support of their efforts to bring this important therapeutic to the millions of patients in the China region with high triglycerides who are at risk of cardiovascular events.” “Amarin has a very dynamic year ahead and we expect to achieve a number of potentially value-creating milestones and to advance our leadership in cardiovascular risk reduction,” concluded Mr. Thero. U.S. Prescription Growth Normalized prescriptions for VASCEPA (prescription of 120 grams of VASCEPA representing a one-month supply) in the United States increased by approximately 39% and 41% in 2020 compared to the same period in 2019 based on data from Symphony Health and IQVIA, respectively, and increased by 17% and 18% in the fourth quarter of 2020 compared to the same period in 2019, respectively. Estimated normalized VASCEPA prescriptions, based on data from Symphony Health and IQVIA, totaled approximately 1,159,000 and 1,076,000 in the fourth quarter of 2020, respectively. Estimated normalized VASCEPA prescriptions, based on data from Symphony Health and IQVIA, totaled approximately 4,484,000 and 4,126,000 in 2020, respectively. While there is no other drug which has the same labeled clinical effects as VASCEPA, prescription growth of VASCEPA in 2020 compared well to the other branded cardiovascular drugs which reported positive cardiovascular outcomes study results in recent years. Following a temporary suspension of in-person promotional activities in March 2020 due to the COVID-19 pandemic and quarantine in the United States, in June 2020 Amarin resumed field-based, face-to-face interactions with healthcare providers, to the extent such healthcare providers allow. For the second half of 2020, substantially all of the company’s field force personnel had the ability to resume face-to-face customer interactions, though such interactions became more challenging in the fourth quarter of 2020 with the resurgence of COVID-19. While Amarin utilizes various means to interact with healthcare professionals virtually and digitally, such interactions tend to be less impactful than frequent in-person communications. This is particularly true for VASCEPA, as it is being newly introduced to many healthcare professionals as a treatment for cardiovascular risk reduction based on its second FDA indication, which had launched in January 2020. Complications in 2020 from COVID-19 were exacerbated as many at-risk patients in 2020 delayed doctors’ visits and blood tests. In the United States, public reports from IQVIA showed patient visits to medical offices for non-emergency medical care were down approximately 70% in April 2020 during the height of the COVID-19 quarantine, with visits increasing thereafter until the resurgence of COVID-19 in the fourth quarter of 2020 when, for example, patient visits in December 2020 again decreased to approximately 50% of pre-COVID-19 levels. As a result of fewer doctors’ visits, fewer lab tests and prioritization of COVID-19 safety, reports in 2020 showed an increase in heart attacks and other urgent cardiovascular events which might have been avoided through preventative cardiovascular risk management. Amarin remains confident that the patient need for VASCEPA in the United States remains high and that as COVID-19 begins to recede, VASCEPA growth will be positioned to accelerate as more patients seek routine doctor visits and lab tests and as our promotional activities become less restricted. In November 2020, a generic version of VASCEPA was launched in the United States, and that generic drug is indicated only as an adjunct to diet for lowering triglyceride levels in adult patients with severe hypertriglyceridemia (TG ≥500 mg/dL), which based on industry data, represents no more than approximately 7% of recent VASCEPA usage and a smaller proportion of the overall market opportunity for VASCEPA. The “skinny label” of this generic product represents no more than approximately $40 million of Amarin’s net product revenue at 2020 prescription levels. The indication for this generic product is limited and we have filed a lawsuit to protect our cardiovascular risk reduction patent rights against what we believe is unlawful infringement by Hikma Pharmaceuticals PLC and a representative healthcare insurance company. Thus far, growth of the generic product has reportedly been limited by lack of qualified supply capacity. Other generic versions of VASCEPA have FDA approval to launch in the United States but have thus far not done so. In late 2020 and early 2021, various managed care companies improved their insurance coverage of branded VASCEPA. In addition, many insurance companies and patients have reported that branded VASCEPA is less expensive to them than the generic version and the wholesale acquisition cost of branded VASCEPA continues to be lower than that of other branded drugs with positive outcomes study results. In these and other ways, this is an atypical generic launch in the United States. Amarin believes the untapped market opportunity in the cardiovascular risk reduction indication is large and that more patients will be helped by VASCEPA with continued investment in market education regarding its benefits. Amarin’s goal is to grow the market faster than generic competition can take share. Amarin intends to vigorously defend its intellectual property rights. European Market Expansion Amarin is seeking to commence commercial sale of VAZKEPA in one or more countries of Europe before the end of 2021. On January 28, 2021, Amarin received a positive CHMP opinion, which recommended marketing authorization be granted for icosapent ethyl in the European Union for cardiovascular risk reduction under the brand name VAZKEPA. Approval of VAZKEPA for marketing and sale by the European Commission is expected in April 2021. The need for preventative cardiovascular care beyond cholesterol management is potentially as large or larger in Europe than the United States. Market access in Europe is managed on a country-by-country basis and, consequently, the timing for receiving market access for each European country will vary significantly. Amarin is planning a staged launch in Europe, including likely launch in 2021 in Germany, Europe’s largest market. In preparation for commercial launch, Amarin’s team in Europe has increased to approximately 50 experienced professionals and is targeted to increase to approximately 200 employees by the end of 2021. Additional information regarding securing market access in Europe and Amarin’s commercialization plans in Europe can be found in the FAQ section under investor relations at www.amarincorp.com. Rest of World China In November 2020, Amarin’s partner in the China region, Edding, shared positive, statistically significant top line results from their Phase 3 clinical trial of VASCEPA. In December 2020, the CSC included icosapent ethyl in its updated Guidelines for Primary Prevention of Cardiovascular Diseases for 2021 as published in the Chinese Journal of Cardiovascular Diseases. In January 2021, VASCEPA was accepted for introduction into the Hainan Boao Lecheng International Medical Tourism Pilot Zone program. Most recently, in Mainland China, the Chinese National Medical Products Administration (NMPA) accepted for review the New Drug Application for VASCEPA. Edding currently anticipates receiving a decision in Mainland China and, separately in Hong Kong, near the end of 2021, followed by steps to ensure that this unique therapy is reimbursed in the major provinces of Mainland China as the first and only drug for its important potential indication for use based on VASCEPA’s demonstrated clinical results. With approximately 180.4 million hypertriglyceridemia (HTG) patients in Mainland China in 2019, representing approximately 20.2% of the adult population and broad use of statin therapy in the country, the medical need for VASCEPA in Mainland China is believed to be high creating a meaningful market opportunity for Amarin and its partner, Edding. Canada, Middle East and Other Cardiovascular disease is a growing public health burden globally. Amarin has elected to pursue VASCEPA approval in limited countries initially with plans to seek regulatory approvals in other geographies after the product is launched and has market access in Europe. Limited exceptions are in select countries of the Middle East and in Canada where promotion of VASCEPA has commenced in a phased manner. Financial Update Net total revenue for the three and twelve months ended December 31, 2020 were $167.3 million and $614.1 million, respectively, compared with $143.3 million and $429.8 million in the corresponding periods of 2019, indicating increases of 17% and 43%, respectively. Net product revenue for the three and twelve months ended December 31, 2020 were $165.9 million and $607.0 million, respectively, compared to $142.0 million and $427.4 million in the corresponding periods of 2019, indicating increases of 17% and 42%, respectively. The increases in net product revenue were driven primarily by increased volume of VASCEPA sales to customers in the United States, as well as a modest increase in VASCEPA’s net selling price in the United States, reflecting various factors including managed care coverage improvements. The increase was also driven by VASCEPA sales outside of the United States of approximately nil and $8.9 million during the three and twelve months ended December 31, 2020 as compared to $0.4 million and $0.7 million during the three and twelve months ended December 31, 2019, primarily as a result of an initial order in the first half of 2020 to ensure adequate product supply for Amarin’s commercial partner’s launch of VASCEPA in Canada (recognized upon shipment by Amarin to our partner). Amarin recognized licensing and royalty revenue of approximately $7.0 million and $2.4 million for the years ended December 31, 2020 and 2019, respectively, from VASCEPA-related commercial progress of our partners in Canada, the China region and the Middle East. Cost of goods sold for the three and twelve months ended December 31, 2020 was $34.8 million and $131.4 million, respectively, compared to $30.7 million and $96.0 million in the corresponding periods of 2019. Amarin’s overall gross margin on net product revenue for the quarter and year ended December 31, 2020 was 79% and 78%, respectively, compared to 78% in the quarter and year ended December 31, 2019, respectively. Selling, general and administrative expenses for the year ended December 31, 2020 was $463.3 million compared with $323.6 million, in the prior year. This increase was primarily due to personnel costs related to the U.S. sales force expansion and European commercial launch preparations. The increase also included an increase in other promotional activities in the United States focused on cardiovascular risk reduction based on VASCEPA’s new label. The level of such promotional activities varied from quarter-to-quarter in 2020 with decreases resulting when the impact of COVID-19 was most pronounced. Research and development expenses for the years ended December 31, 2020 and 2019 were $39.0 million and $34.4 million, respectively. This increase reflects support of numerous publications regarding results of the REDUCE-IT cardiovascular outcomes study, costs and fees related to regulatory reviews of VASCEPA, particularly in Europe, together with costs associated with exploratory development, including costs of pilot studies of VASCEPA for other potential uses such as the potential use of VASCEPA as a therapy to help mitigate patient risks and symptoms of COVID-19. Under U.S. GAAP, Amarin reported a net loss of $18.0 million for the year ended December 31, 2020, or basic and diluted loss per share of $0.05. This net loss included $45.8 million in non-cash stock-based compensation expense. For the year ended December 31, 2019, Amarin reported a net loss of $22.6 million, or basic and diluted loss per share of $0.07. This net loss included $30.9 million in non-cash stock-based compensation expense. Excluding non-cash stock-based compensation expense, non-GAAP adjusted net income was $27.8 million for the year ended December 31, 2020, or non-GAAP adjusted basic and diluted earnings per share of $0.07, compared to non-GAAP adjusted net income of $8.3 million for the year ended December 31, 2019, or non-GAAP adjusted basic and diluted earnings per share of $0.02. As of December 31, 2020, Amarin reported aggregate cash and investments of $563.4 million, consisting of cash and cash equivalents of $187.0 million and liquid short-term and long-term investments of $314.0 million and $62.5 million, respectively. As of December 31, 2020, Amarin reported $154.6 million in net accounts receivable ($203.9 million in gross accounts receivable before allowances and reserves) and $188.9 million in inventory. Furthermore, the final royalty-like debt payment was made during the fourth quarter of 2020, which previously had been 10% of net product revenue since VASCEPA was launched, resulting in Amarin having no debt. As of December 31, 2020, Amarin had approximately 392.5 million ADSs and ordinary shares outstanding, nil common share equivalents of Series A Convertible Preferred Shares outstanding and approximately 16.7 million equivalent shares underlying stock options at a weighted-average exercise price of $8.00, as well as 7.7 million equivalent shares underlying restricted or deferred stock units. Conference Call and Webcast Information: Amarin will host a conference call February 25, 2021, at 7:30 a.m. ET to discuss this information. The conference call can be heard live on the investor relations section of the company's website at www.amarincorp.com, or via telephone by dialing 877-545-0320 within the United States, 973-528-0016 from outside the United States, and referencing conference ID 635842. A replay of the call will be made available for a period of two weeks following the conference call. To hear a replay of the call, dial 877-481-4010, PIN: 40090. A replay of the call will also be available through the company's website shortly after the call. Use of Non-GAAP Adjusted Financial Information Included in this press release are non-GAAP adjusted financial information as defined by U.S. Securities and Exchange Commission Regulation G. The GAAP financial measure most directly comparable to each non-GAAP adjusted financial measure used or discussed, and a reconciliation of the differences between each non-GAAP adjusted financial measure and the comparable GAAP financial measure, is included in this press release after the condensed consolidated financial statements. Non-GAAP adjusted net income was derived by taking GAAP net (loss) income and adjusting it for non-cash stock-based compensation expense. Management uses these non-GAAP adjusted financial measures for internal reporting and forecasting purposes, when publicly providing its business outlook, to evaluate the company’s performance and to evaluate and compensate the company’s executives. The company has provided these non-GAAP financial measures in addition to GAAP financial results because it believes that these non-GAAP adjusted financial measures provide investors with a better understanding of the company’s historical results from its core business operations. While management believes that these non-GAAP adjusted financial measures provide useful supplemental information to investors regarding the underlying performance of the company’s business operations, investors are reminded to consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with the company’s results of operations as determined in accordance with GAAP. In addition, it should be noted that these non-GAAP financial measures may be different from non-GAAP measures used by other companies, and management may utilize other measures to illustrate performance in the future. About Amarin Amarin is a rapidly growing, innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our scientific research foundation to our focus on clinical trials, and now our commercial expansion, we are evolving and growing. In 2009, Amarin had fewer than twenty employees. Today, with offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, and Zug in Switzerland, Amarin has approximately 1,000 employees and commercial partners and suppliers around the world. We are committed to rethinking cardiovascular risk through the advancement of scientific understanding of the impact on society of significant residual risk that exists beyond traditional therapies, such as statins for cholesterol management. About REDUCE-IT REDUCE-IT was a global cardiovascular outcomes study designed to evaluate the effect of VASCEPA in adult patients with LDL-C controlled to between 41-100 mg/dL (median baseline 75 mg/dL) by statin therapy and various cardiovascular risk factors including persistent elevated triglycerides between 135-499 mg/dL (median baseline 216 mg/dL) and either established cardiovascular disease (secondary prevention cohort) or diabetes mellitus and at least one other cardiovascular risk factor (primary prevention cohort). REDUCE-IT, conducted over seven years and completed in 2018, followed 8,179 patients at over 400 clinical sites in 11 countries with the largest number of sites located within the United States. REDUCE-IT was conducted based on a special protocol assessment agreement with FDA. The design of the REDUCE-IT study was published in March 2017 in Clinical Cardiology.1 The primary results of REDUCE-IT were published in The New England Journal of Medicine in November 2018.2 The total events results of REDUCE-IT were published in the Journal of the American College of Cardiology in March 2019.3 These and other publications can be found in the R&D section on the company’s website at www.amarincorp.com. About VASCEPA® (icosapent ethyl) Capsules VASCEPA (icosapent ethyl) capsules are the first-and-only prescription treatment approved by the U.S. FDA comprised solely of the active ingredient, icosapent ethyl (IPE), a unique form of eicosapentaenoic acid. VASCEPA was launched in the United States in January 2020 as the first and only drug approved by the U.S. FDA for treatment of the studied high-risk patients with persistent cardiovascular risk after statin therapy. VASCEPA was initially launched in the United States in 2013 based on the drug’s initial FDA approved indication for use as an adjunct therapy to diet to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. Since launch, VASCEPA has been prescribed over ten million times. VASCEPA is covered by most major medical insurance plans. In addition to the United States, VASCEPA is approved and sold in Canada, Lebanon and the United Arab Emirates. In Europe, approval is anticipated in April 2021 following the January 28, 2021 favorable opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending that marketing authorisation be granted to icosapent ethyl in the European Union for the reduction of risk of cardiovascular events in patients at high cardiovascular risk, under the brand name VAZKEPA®. Indications and Limitation of Use (in the United States)VASCEPA is indicated: As an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and established cardiovascular disease ordiabetes mellitus and two or more additional risk factors for cardiovascular disease. As an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia. The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined. Important Safety Information VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components.VASCEPA was associated with an increased risk (3% vs 2%) of atrial fibrillation or atrial flutter requiring hospitalization in a double-blind, placebo-controlled trial. The incidence of atrial fibrillation was greater in patients with a previous history of atrial fibrillation or atrial flutter.It is not known whether patients with allergies to fish and/or shellfish are at an increased risk of an allergic reaction to VASCEPA. Patients with such allergies should discontinue VASCEPA if any reactions occur.VASCEPA was associated with an increased risk (12% vs 10%) of bleeding in a double-blind, placebo-controlled trial. The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel or warfarin.Common adverse reactions in the cardiovascular outcomes trial (incidence ≥3% and ≥1% more frequent than placebo): musculoskeletal pain (4% vs 3%), peripheral edema (7% vs 5%), constipation (5% vs 4%), gout (4% vs 3%), and atrial fibrillation (5% vs 4%).Common adverse reactions in the hypertriglyceridemia trials (incidence >1% more frequent than placebo): arthralgia (2% vs 1%) and oropharyngeal pain (1% vs 0.3%).Adverse events may be reported by calling 1-855-VASCEPA or the FDA at 1-800-FDA-1088.Patients receiving VASCEPA and concomitant anticoagulants and/or anti-platelet agents should be monitored for bleeding. Key clinical effects of VASCEPA on major adverse cardiovascular events are included in the Clinical Studies section of the prescribing information for VASCEPA as set forth below: Effect of VASCEPA on Time to First Occurrence of Cardiovascular Events in Patients with Elevated Triglyceride levels and Other Risk Factors for Cardiovascular Disease in REDUCE-IT VASCEPAPlaceboVASCEPA vs PlaceboN = 4089n (%)Incidence Rate (per 100 patient years)N = 4090n (%)Incidence Rate (per 100 patient years)Hazard Ratio (95% CI)Primary composite endpointCardiovascular death, myocardial infarction, stroke, coronary revascularization, hospitalization for unstable angina (5-point MACE)705(17.2)4.3901(22.0)5.70.75(0.68, 0.83)Key secondary composite endpointCardiovascular death, myocardial infarction, stroke (3-point MACE)459(11.2)2.7606(14.8)3.70.74(0.65, 0.83)Other secondary endpointsFatal or non-fatal myocardial infarction250(6.1)1.5355(8.7)2.10.69(0.58, 0.81)Emergent or urgent coronary revascularization216(5.3)1.3321(7.8)1.90.65(0.55, 0.78)Cardiovascular death [1]174(4.3)1.0213(5.2)1.20.80(0.66, 0.98)Hospitalization for unstable angina [2]108(2.6)0.6157(3.8)0.90.68(0.53, 0.87)Fatal or non-fatal stroke98(2.4)0.6134(3.3)0.80.72(0.55, 0.93)[1] Includes adjudicated cardiovascular deaths and deaths of undetermined causality.[2] Determined to be caused by myocardial ischemia by invasive/non-invasive testing and requiring emergent hospitalization. FULL U.S. FDA-APPROVED VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT WWW.VASCEPA.COM. Forward-Looking Statements This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including expectations regarding financial metrics and performance such as prescription growth, revenue growth, operating expenses, inventory purchases, and managed care coverage for VASCEPA, including the impact of the COVID-19 pandemic, the outcome of patent litigation and the launch of generic competition on these metrics; the timing and outcome of regulatory reviews, recommendations and approvals and related reimbursement decisions and commercial launches in the China region, Europe and elsewhere; plans for Amarin’s expected launch of VASCEPA directly in major markets in Europe, directly and indirectly; the timing and outcome of Amarin’s patent litigation efforts; the timing and outcome of promotion activities, including patient-oriented campaigns and education of healthcare professionals; commercial and international expansion, prescription growth and revenue growth and future revenue levels, including the contributions of sales representatives; the sufficiency of current capital resources to achieve sustained positive cash flows; the availability of commercial supply to generic companies and Amarin; expectations related to exclusivity in various jurisdictions and ongoing patent litigation efforts and associated business plans in various scenarios; and the impact of the COVID-19 pandemic on all of the forgoing. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Amarin's ability to effectively commercialize VASCEPA and maintain or grow market share will depend in part on Amarin’s ability to continue to effectively finance its business, efforts of third parties, Amarin’s ability to create and increase market demand for VASCEPA through education, marketing and sales activities, to achieve broad market acceptance of VASCEPA, to receive adequate levels of reimbursement from third-party payers, to develop and maintain a consistent source of commercial supply at a competitive price, to comply with legal and regulatory requirements in connection with the sale and promotion of VASCEPA and to secure, maintain and defend its patent protection for VASCEPA. Among the factors that could cause actual results to differ materially from those described or projected herein include the following: the possibility that VASCEPA may not receive regulatory approval in Europe, the China region or other geographies on the expected timelines or at all, the risk that additional generic versions of VASCEPA will enter the market and that generic versions of VASCEPA will achieve greater market share and more commercial supply than anticipated, uncertainties associated generally with research and development, clinical trials and related regulatory approvals; the risk that sales may not meet expectations and related cost may increase beyond expectations; the risk that patents may be determined to not be infringed or not be valid in patent litigation and applications may not result in issued patents sufficient to protect the VASCEPA franchise. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including Amarin’s annual report on Form 10-K for the year ended December 31, 2020, filed on the date hereof. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. Amarin’s forward-looking statements do not reflect the potential impact of significant transactions the company may enter into, such as mergers, acquisitions, dispositions, joint ventures or any material agreements that Amarin may enter into, amend or terminate. Availability of Other Information About AmarinInvestors and others should note that Amarin communicates with its investors and the public using the company website (www.amarincorp.com), the investor relations website (investor.amarincorp.com), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media, and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933. Amarin Contact InformationInvestor Inquiries:Investor RelationsAmarin Corporation plcIn U.S.: +1 (908) 719-1315 IR@amarincorp.com (investor inquiries) Solebury Troutamarinir@troutgroup.com Media Inquiries:CommunicationsAmarin Corporation plcIn U.S.: +1 (908) 892-2028 PR@amarincorp.com (media inquiries) CONSOLIDATED BALANCE SHEET DATA (U.S. GAAP) Unaudited * December 31, 2020 December 31, 2019 (in thousands) ASSETS Current Assets: Cash and cash equivalents $186,964 $644,588 Restricted cash 3,915 3,907 Short-term investments 313,969 — Accounts receivable, net 154,574 116,430 Inventory 188,864 76,769 Prepaid and other current assets 30,947 13,311 Total current assets 879,233 855,005 Property, plant and equipment, net 2,016 2,361 Long-term investments 62,469 — Operating lease right-of-use asset 8,054 8,511 Other long-term assets 432 1,074 Intangible asset, net 13,817 15,258 TOTAL ASSETS $966,021 $882,209 LIABILITIES AND STOCKHOLDERS’ EQUITY Current Liabilities: Accounts payable $105,876 $49,950 Accrued expenses and other current liabilities 198,641 139,826 Debt from royalty-bearing instrument — 50,130 Current deferred revenue 2,926 2,342 Total current liabilities 307,443 242,248 Long-Term Liabilities: Long-term deferred revenue 15,706 18,504 Long-term operating lease liability 9,153 9,443 Other long-term liabilities 6,214 3,751 Total liabilities 338,516 273,946 Stockholders’ Equity: Preferred stock — 21,850 Common stock 290,115 269,173 Additional paid-in capital 1,817,649 1,764,317 Treasury stock (51,082) (35,900)Accumulated deficit (1,429,177) (1,411,177)Total stockholders’ equity 627,505 608,263 TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $966,021 $882,209 * Unaudited as a standalone schedule; copied from consolidated financial statements CONSOLIDATED STATEMENTS OF OPERATIONS DATA (U.S. GAAP) Unaudited * Three Months Ended December 31, Year Ended December 31, (in thousands, except per share amounts) (in thousands, except per share amounts) 2020 2019 2020 2019 Product revenue, net$165,907 $142,044 $607,025 $427,391 Licensing and royalty revenue 1,344 1,233 7,035 2,364 Total revenue, net 167,251 143,277 614,060 429,755 Less: Cost of goods sold 34,769 30,665 131,444 96,019 Gross margin 132,482 112,612 482,616 333,736 Operating expenses: Selling, general and administrative (1) 116,816 96,025 463,312 323,623 Research and development (1) 8,508 11,097 38,959 34,392 Total operating expenses 125,324 107,122 502,271 358,015 Operating income (loss) 7,158 5,490 (19,655) (24,279)Interest income 551 3,074 4,901 8,499 Interest expense (163) (1,439) (2,605) (6,626)Other income (expense), net 54 107 104 (75)Income (loss) from operations before taxes 7,600 7,232 (17,255) (22,481)Provision for income taxes (2,674) (164) (745) (164)Net income (loss) 4,926 7,068 (18,000) (22,645)Earnings (loss) per share Basic$0.01 $0.02 $(0.05) $(0.07)Diluted$0.01 $0.02 $(0.05) $(0.07)Weighted average shares outstanding: Basic 390,661 359,156 381,759 342,538 Diluted 398,963 401,039 381,759 342,538 * Unaudited as a standalone schedule; copied from consolidated financial statements (1) Excluding non-cash stock-based compensation, selling, general and administrative expenses were $424,067 and $297,321 for 2020 and 2019, respectively, and research and development expenses were $32,391 and $29,777, respectively, for the same periods. RECONCILIATION OF NON-GAAP NET INCOME Unaudited Three months ended December 31, Year Ended December 31, (in thousands, except per share amounts) (in thousands, except per share amounts) 2020 2019 2020 2019 Net income (loss) for EPS - GAAP 4,926 7,068 (18,000) (22,645)Stock-based compensation expense 11,508 8,188 45,814 30,917 Adjusted net income for EPS - non-GAAP $16,434 $15,256 $27,814 $8,272 basic and diluted Earnings per share: Basic - non-GAAP $0.04 $0.04 $0.07 $0.02 Diluted - non-GAAP $0.04 $0.04 $0.07 $0.02 Weighted average shares: Basic 390,661 359,156 381,759 342,538 Diluted 398,963 401,039 401,195 386,797 1 Bhatt DL, Steg PG, Brinton E, et al., on behalf of the REDUCE-IT Investigators. Rationale and Design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial. Clin Cardiol. 2017;40:138-148.2 Bhatt DL, Steg PG, Miller M, et al., on behalf of the REDUCE-IT Investigators. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380:11-22.3 Bhatt DL, Steg PG, Miller M, et al., on behalf of the REDUCE-IT Investigators. Reduction in first and total ischemic events with icosapent ethyl across baseline triglyceride tertiles. J Am Coll Cardiol. 2019;74:1159-1161.
The pair received ‘substantial compensation’ and a public apology from Mirror Group Newspapers.
25, 2021 /CNW/ - CIBC (TSX: CM) (NYSE: CM) today announced its financial results for the first quarter ended January 31, 2021.First quarter highlights Q1/21Q1/20Q4/20YoY VarianceQoQ Variance Reported Net Income$1,625 million$1,212 million$1,016 million+34%+60% Adjusted Net Income (1)$1,640 million$1,483 million$1,280 million+11%+28% Reported Diluted Earnings Per Share (EPS)$3.
Iran dismissed as "immature" a statement by a U.N. investigator that inconsistencies in its explanation of the shooting down of a Ukrainian passenger plane last year raised questions over whether the act was intentional, Iranian media said on Thursday. All 176 people aboard the Ukraine International Airlines Flight PS752, most of them Canadian, were killed when the plane crashed shortly after takeoff en route from Tehran to Kiev on Jan. 8, 2020. Agnes Callamard, the U.N. special rapporteur on extrajudicial, summary or arbitrary executions, said on Tuesday she had found no concrete evidence the plane was targeted intentionally but that Iran had not proven it was accidental.
Dublin, Feb. 25, 2021 (GLOBE NEWSWIRE) -- The "Gas Meters Smart & Standard Ed 4 2021" report has been added to ResearchAndMarkets.com's offering. Smart gas metering is gaining momentum, with the expansion of the Chinese natural gas market, European rollouts accelerating and the US continuing to convert to AMR and AMI metering. Nationwide stocks of diaphragm meters are being converted by replacements with smart meters, or with the addition of communication modules to the existing well-tested diaphragm and rotary meters. The report charts these developments over a ten-year time frame from 2015 and forecast to 2025. The market is split by residential, standard and AMR/AMI, PPM, communication modules, C&I and grid meters and analysed by country. Global gas meter demand is forecast in units and value, totals of all meters and smart meters, from the base year 2015 to 2025 in the countries with piped gas networks and over 600,000 gas customers. Analysis of sales of gas meters for 43 countries, by meter type - Basic Residential, AMR/ AMI, Prepayment, Communications Modules, C&I - units, value, and average selling price, from 2019 to 2025. Tables of the global total, regional totals and countries. The major meter technologies are described with total market shares; diaphragm, rotary, turbine, orifice and ultrasonic, plus outline of Coriolis, vortex and MEMS meters. The major customers for gas meters, the gas transmission and distribution utilities, are outlined in each of the 43 countries profiled, together with their structure. The number of housing units, residential and commercial gas customers with piped gas are charted for each profiled country, from 1900 to 2020. At the city gate station, gas pressure is high, grid and bulk meters need to be robust and highly accurate. Commercial & Industrial (C&I) meters contributed only 1% of meter sales in units in 2019, but this important segment of high value meters was worth $1 billion. Global market shares are accompanied by profiles of the meter manufacturers, including those with small shares in numbers of meters but leading positions in high end meters for high-pressure measurement - Elster, Itron, Landis+Gyr, Dresser, Diehl, Apator, Sagemcom, Sensus, Dongfa Group, Holley, Emerson. Fundamental changes in the demand cycle for meters are taking place in the residential segment. Meter vendors need to understand the new trends to plan their footprint and to avoid mismatch, over-capacity and pressure on profits. Historically the demand for gas meters followed a stable long-term path, driven by the increase of gas penetration, first for city coal gas and then for natural gas. The country-wide deployments of smart meters now starting, involve replacing the entire stock of residential meters with 20-year lives, in a short period of perhaps 5 years. This has never happened before and it means that there will be peaks of replacement and troughs of low demand. The NGV and Autogas segment is reviewed, a small but growing segment for gas meters, with numbers and metering technology. Gas metering cannot be fully understood in isolation. It is not all piped natural gas. Marketers need to understand the gas supply industry, how it has developed and where it will go in the future. The industry is described, from its start with local town gas to the international natural gas industry, today piped and LNG. There are still other pockets of gas; town gas, LPG both piped and in cylinders and local tanks of natural gas. Key Topics Covered: 1. The Gas Metering Landscape in 2020 2. World Demand for Gas Meters from 2019 to 2025 Meter DemandGas Meter Technology Shares 3. Demand for Smart Gas Meters 4. Long-Term Demand Trend for Gas Meters Demand 5. Gas Distribution System Gas PressureThe Gathering SystemThe Transmission SystemCompressor StationsLine PackGate StationsThe Distribution NetworkThe Final Stage, Moving Natural Gas into the Home 6. Meter Types from 1843 to the Future Positive Displacement of Gas MetersDiaphragm MetersRotary MetersInferential MetersTurbine MetersOrifice MetersUltrasonic Flow MetersIntelligent Micom MetersCoriolis MetersVortex MetersMems (Micro-Electro-Mechanical System)Smart/Advanced MetersCommunication ModuleTurndown Ratio and RangeabilityTypical Turndown Ratio of Various Meter TypesMeter Sizes - GHeating Value 7. The Gas Meter Market in Europe Establishment of Gas in EuropeSmart MetersMeter DemandAustriaSmart MetersMeter DemandBelgiumSmart MetersCost-Benefit Analysis ProjectsMeter DemandBulgariaSmart MetersMeter DemandCzech RepublicSmart MetersMeter DemandDenmarkSmart MetersMeter DemandEstoniaFinlandSmart MetersMeter DemandFranceSmart MetersMeter DemandGermanySmart MetersMeter DemandGreeceSmart MetersMeter DemandHungarySmart MetersMeter DemandIrelandSmart MetersMeter DemandItalySmart MetersMeter DemandLatviaMeter DemandLithuaniaSmart MetersMeter DemandNetherlandsSmart MetersMeter DemandPolandSmart Meter ProgressMeter DemandPortugalSmart MetersMeter DemandRomaniaSmart MetersMeter DemandSlovak RepublicSmart MetersMeter DemandSloveniaSmart MetersMeter DemandSpainSmart MetersMeter DemandSwedenSmart MetersMeter DemandSwitzerlandSmart MetersMeter DemandTurkeyPrepayment Gas MetersSmart Meter ProgressMeter DemandUnited KingdomCertificationRemanufacturing Meters for the Secondary or Sub-Metering MarketSmart MetersPulse Transmission of Data for AmrMeter Demand 8. The Gas Meter Market in the CIS Smart MetersMeter DemandRussiaMeter DemandMeter ManufacturersUkraineSmart Meter ProgressMeter DemandMeter Manufacturers 9. The Gas Meter Market in the Middle East IranMeter DemandMeter Manufacturers 10. The Gas Meter Market in Africa North AfricaMeter DemandAlgeriaMeter ManufacturersEgyptMeter ManufacturersSub-Saharan Africa 11. The Gas Meter Market in Asia-Pacific Meter Demand Asia-PacificAustraliaSmart Meter ProgressMeter DemandChinaThe Development of Distributed Gas in ChinaManufactured GasLPGNatural GasCity Gas PlayersSmart Meter ProgressMeter DemandMeter ManufacturersIndiaSmart Meter ProgressIndonesiaSmart Meter ProgressMeter DemandJapanThe Intelligent Micom Gas MeterUltrasonic Intelligent Gas MeterSmart MetersLpg MetersMeter DemandMeter ManufacturersSouth KoreaSmart MetersMeter DemandMeter ManufacturersNew ZealandSmart Meter ProgressMeter DemandPakistanMeter DemandTaiwanSmart MetersMeter DemandMeter ManufacturersThailand 12. The Gas Meter Market in North America United StatesGas Industry StructureSmart MetersMeter DemandMeter ManufacturersCanadaSmart MetersMeter DemandMexicoMeter Demand 13. The Gas Meter Market in South America Meter DemandArgentinaMeter DemandBrazilMeter DemandChileMeter DemandColombiaMeter Demand 14. The Gas Meter Market in Central America 15. Competitive Analysis, Company Profiles and Market Shares ElsterItronLandis+GyrDresserDiehlApatorSagemcomSensusDongfa GroupHolleyEmersonDNV GL 16. NGV and Autogas Metering 17. The Origins of the Global Gas Industry Electricity Versus Gas 18. Gas Sources, Types and Delivery Gas CategoriesNatural GasManufactured GasCoke-Oven GasLiquefied Petroleum Gas (LPG)Coal GasBiogasBlast Furnace GasGas HydratesRefinery GasSyngas - SngPg AutogasGas Delivery and StoragePiped GasNatural Gas Liquids, Liquefied Natural Gas (Lng)Liquefied Petroleum Gas (Lpg)Compressed Natural Gas (Cng) 19. Methodology For more information about this report visit https://www.researchandmarkets.com/r/1owxyf CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Deutsche Telekom's Slovak Telekom business cannot avoid sanctions imposed by Slovak antitrust authorities even though it has already been penalised by EU competition enforcers, the EU's top court ruled on Thursday. The case came before the Luxembourg-based Court of Justice of the European Union after Slovak Telekom questioned the legality of the Slovak watchdog's 17.45-million-euro ($21 million) fine levied in 2009 as a result of the company using below-cost prices to squeeze out competitors. The European Commission in 2014 fined the company for squeezing competitors by charging unfair wholesale prices in Slovakia, which followed an investigation that began in 2009.
The jobs of 1,000 workers, and many more in the supply chain, depend on the factory.
A miles-long traffic jam caused travel delays in Vallirana, Spain, on February 25.This helicopter footage, posted to Twitter by the Catalan Traffic Service, shows the snarl-up from the air on Thursday morning.The Catalan Traffic Service said traffic on the B-24 towards Barcelona was being diverted onto the N-340, which had a traffic jam six kilometers long. Credit: @transit via Storyful
A step forward for the circular economy: Polymateria open-sources recyclability data to show first recyclable and biodegradable plastic material
Washington (US), February 25 (ANI): Researchers in Munich during a recent study discovered how the length of allergy seasons in Germany are affected by pollen travelling far distances.
Researchers are developing new technology to help reduce human-elephant conflicts.
What's an 11-letter word that describes a stock market crash? Major market downturns present opportunities for investors who have a long-term perspective to buy fantastic stocks at a discount. Fiverr (NYSE: FVRR) provides a platform that connects freelancers with buyers of digital services.
Growing construction industry and changing interior décor preferences of customers are driving the market for doors. However, high investment & installation costs of eco-friendly doors is expected to restrain this market.New York, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Doors Market by Material, Mechanism, Product Type, Mode of Application, Application And Region - Global Forecast to 2025" - https://www.reportlinker.com/p05339880/?utm_source=GNW Rapid urbanization in emerging economies is expected to offer significant growth opportunities to manufacturers of doors. The major challenge faced by players are fluctuating raw material prices and growing environmental concerns and implementation of standards in door products.In terms of value, the wood segment is projected to account for the largest share of the doors market, by material, during the forecast period.Wood is projected to be the largest material segment in doors market. Wooden doors are aesthetically appealing; however, they are less thermally efficient, expensive, absorb moisture and easily rot which leads to high maintenance costs.Swinging doors is projected to register the highest CAGR during the forecast period.Swinging doors segment is the fastest growing mechanism used for door systems and contributing the largest share to the global doors systems market. These are more cost-effective and require lesser maintenance as compared to folding, revolving, and sliding doors.In terms of value, the Interior doors segment is projected to account for the largest share of the doors market, by product type, during the forecast period.Interior doors is the largest product type segment in doors market.These doors are lighter, thinner, and smaller in comparison to exterior doors.They are not soundproof or weather proof as they do not include weather-stripping features. Changing lifestyles and growing expenditure on residential buildings drives the market for interior doors.Residential doors is projected to register the highest CAGR during the forecast period.Residential segment is the fastest growing product type in the doors market.This is attributed to the changing preferences and trends, which could require renovations and replacements.There is a rise in demand for green buildings, especially in the North American market as there are various regulations in place that make it obligatory to use sustainable and energy-efficient materials in both, commercial and residential buildings.In terms of value, the new construction segment is projected to account for the largest share of the doors market, by mode of appplication, during the forecast period.Based on the mode of application, the doors market has been segmented into aftermarket and new construction.In 2019, the new construction segment dominated the doors market.This is attributed to the changing preferences and trends, which could require renovation and remodeling. The demand for doors is expected to be driven by factors such as reduced noise, better comfort, and greater aesthetic appeal.The APAC region leads the doors market in terms of value.APAC is the fastest-growing region for doors market.The growth in demand for doors in the region can be largely attributed to the growing infrastructure and building & construction industries.The demand for customized doors is growing rapidly in the region, owing to the high demand from the infrastructural sector for aesthetic appeal. As a result, the market has been positively impacted.In-depth interviews were conducted with Chief Executive Officers (CEOs), marketing directors, other innovation and technology directors, and executives from various key organizations operating in the fresh food packaging market, and information was gathered from secondary research to determine and verify the market size of several segments.• By Company Type: Tier 1 – 40%, Tier 2 – 35%, and Tier 3 – 25%• By Designation: C Level Executives– 35%, Directors – 40%, and Others – 25%• By Region: APAC – 40%, Europe – 10%, North America – 25%, the Middle East & Africa – 15%, and South America- 10%Major players operating in the global doors market include Assa Abloy (Sweden), Droma Kaba (Switzerland), (Ireland), Masonite (US), Andersen Corporation (US), Simpson Door Company (US), Jeld-Wen, Inc. (US), PGT (US), Fancy Doors & Mouldings (Canada), Cornerstone Building Brands (US), ARCAT (US), Lacantina Doors (US), Boon Edam (Netherlands), Pella Corporation (US), The Lyon & Billard Lumber Co. (US), Atrium (US), Fenesta (India), Corinthian Doors (Australia), Hormann (Germany), MI Windows and Doors, LLC (US), Novoferm Gmbh (Germany), Marvin (US), Viwintech Window & Door Inc. (US), Therma-Tru Corp. (US), and OCM Industrial Doors (Italy).Research Coverage:This report provides detailed segmentation of the doors market based on material, mechanism, product type, application, and mode of application.Based on mechanism, the doors market has been segmented into folding, sliding, swinging, overhead, and others.Based on the product type, the doors market has been segmented into interior doors and exterior doors.Based on the application, the doors market has been segmented into residential, and non-residential.Based on the mode of application, the doors market has been segmented into aftermarket and new construction.Key Benefits of Buying the ReportFrom an insight perspective, this research report focuses on various levels of analyses — industry analysis (industry trends), market share ranking of top players, and company profiles, which together comprise and discuss the basic views on the competitive landscape; emerging and high-growth segments of the commodity plastics market; high growth regions; and market drivers, restraints, opportunities, and challenges.Read the full report: https://www.reportlinker.com/p05339880/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
Thousands of Indonesia's religious figures gathered on Thursday for mass COVID-19 inoculations for clergy and faith groups, with monks, priests, imams and nuns queuing to receive their first doses of vaccine. Monks in orange, brown and maroon robes sat on chairs evenly spaced across the basement car park of Jakarta's Grand Istiqlal Mosque waiting to register for Sinovac Biotech's CoronaVac. Vajra Sastra, a 22-year-old monk, said he hoped more could receive the vaccine sooner so his temple could reopen again for mass prayers.